Phillip Lepper sold $45k of ATER
Chief Commercial Officer at Aterian, Inc.. 27,532 shares at an average of $1.65, traded May 20, 2025, filed May 22, 2025.
Score components
- +15RoleOfficer
- +6Trade size$45k at market
- +5Share of holdings soldSold 15% of holdings
- 0ClusterNo other insider selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001437749-25-018184, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| May 20, 2025 | SOpen-market sale Common Stock | -27,532 | $1.65 | $45k | 150,402 | May 22, 2025 |
Related signals
Other insiders at Aterian, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 35Weak | Aterian, Inc. | Roi Zion Zahut Chief Technology Officer | $27k 20,880 shares | -5% | |
| 37Weak | Aterian, Inc. | Joshua O Feldman Chief Financial Officer | $22k 16,576 shares | -4% | |
| 48Moderate | Aterian, Inc. | Arturo Rodriguez Chief Executive Officer | $68k 52,257 shares | -5% | |
| 35Weak | Aterian, Inc. | William Kurtz director | $14k 9,722 shares | -21% | |
| 23Weak | Aterian, Inc. | Phillip Lepper Chief Revenue Officer | $4,021 1,711 shares | -1% | |
| 23Weak | Aterian, Inc. | Roi Zion Zahut Chief Technology Officer | $8,681 3,694 shares | -2% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.